Consensus guidelines for the use and interpretation of angiogenesis assays

P Nowak-Sliwinska, K Alitalo, E Allen, A Anisimov… - Angiogenesis, 2018 - Springer
The formation of new blood vessels, or angiogenesis, is a complex process that plays
important roles in growth and development, tissue and organ regeneration, as well as …

Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat

TM Maher, ME Strek - Respiratory research, 2019 - Springer
Idiopathic pulmonary fibrosis (IPF) is a progressive disease with a dismal prognosis. The
average life expectancy of untreated patients with IPF is only 3 to 4 years. Decline in forced …

Nintedanib for systemic sclerosis–associated interstitial lung disease

O Distler, KB Highland, M Gahlemann… - … England Journal of …, 2019 - Mass Medical Soc
Background Interstitial lung disease (ILD) is a common manifestation of systemic sclerosis
and a leading cause of systemic sclerosis–related death. Nintedanib, a tyrosine kinase …

[HTML][HTML] Therapeutic effect of Sirtuin 3 on ameliorating nonalcoholic fatty liver disease: the role of the ERK-CREB pathway and Bnip3-mediated mitophagy

R Li, T Xin, D Li, C Wang, H Zhu, H Zhou - Redox Biology, 2018 - Elsevier
Increased mitochondrial damage is related to the progression of a diet-induced nonalcoholic
fatty liver disease. The aim of our study is to investigate the role of Sirtuin 3 (Sirt3) in treating …

Fibrosing interstitial lung diseases: knowns and unknowns

V Cottin, L Wollin, A Fischer… - European …, 2019 - Eur Respiratory Soc
Patients with certain types of fibrosing interstitial lung disease (ILD) are at risk of developing
a progressive phenotype characterised by self-sustaining fibrosis, decline in lung function …

BI 1015550 is a PDE4B inhibitor and a clinical drug candidate for the oral treatment of idiopathic pulmonary fibrosis

FE Herrmann, C Hesslinger, L Wollin… - Frontiers in …, 2022 - frontiersin.org
The anti-inflammatory and immunomodulatory abilities of oral selective phosphodiesterase
4 (PDE4) inhibitors enabled the approval of roflumilast and apremilast for use in chronic …

Inhaled treprostinil and forced vital capacity in patients with interstitial lung disease and associated pulmonary hypertension: a post-hoc analysis of the INCREASE …

SD Nathan, A Waxman, S Rajagopal… - The Lancet …, 2021 - thelancet.com
Background INCREASE was a randomised, placebo-controlled, phase 3 trial that evaluated
inhaled treprostinil in patients with interstitial lung disease (ILD) and associated pulmonary …

[图书][B] Microcomputed tomography: methodology and applications

SR Stock - 2019 - taylorfrancis.com
MicroComputed Tomography has become the gold standard for studying 3D microscopic
structures nondestructively, and this book provides up-to-date coverage of the modality. The …

ER–mitochondria microdomains in cardiac ischemia–reperfusion injury: a fresh perspective

H Zhou, S Wang, S Hu, Y Chen, J Ren - Frontiers in Physiology, 2018 - frontiersin.org
The mitochondrial and endoplasmic reticulum (ER) homeostasis is pivotal to the
maintenance of an array of physiological processes. The physical contact and association …

Differential effects of Nintedanib and Pirfenidone on lung alveolar epithelial cell function in ex vivo murine and human lung tissue cultures of pulmonary fibrosis

M Lehmann, L Buhl, HN Alsafadi, S Klee… - Respiratory …, 2018 - Springer
Background Idiopathic pulmonary fibrosis (IPF) is a fatal interstitial lung disease. Repetitive
injury and reprogramming of the lung epithelium are thought to be critical drivers of disease …